Product Description
asapiprant is a potent and selective DP1 receptor antagonist, and exerts suppressive effects in the animal models of allergic diseases. Thus, asapiprant has potential as a novel therapy for allergic airway diseases. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26277322/)
Mechanisms of Action: PGD2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shionogi
Company Location: OSAKA M0 541-0045
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Rhinitis, Allergic, Seasonal|Rhinitis, Allergic, Perennial
Phase 2: Rhinitis, Allergic, Perennial|Rhinitis, Allergic|Rhinitis, Allergic, Seasonal|COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BGE-175-201 | P2 |
Terminated |
COVID-19 |
2022-04-20 |
|
| 1210D1526 | P2 |
Completed |
Rhinitis, Allergic, Seasonal |
2012-11-01 |
33% |
| 2008-006788-35 | P2 |
Completed |
Rhinitis, Allergic |
2009-07-17 |
|
| 2008-006787-11 | P2 |
Completed |
Rhinitis, Allergic |
2009-05-30 |